Sponsors (8)
The bill tightens safety-oriented limits on how medication abortion is provided to Medicare beneficiaries, but at the cost of significantly reduced access for patients and increased legal and programmatic risk for providers.
Medicare enrollees will have clearer, stricter rules requiring physician presence and in-person evaluation for medication abortions, which proponents argue could reduce risks from remote or non-physician provision.
Medicare patients (especially women, rural beneficiaries, and people with mobility limitations) will face substantially reduced access to medication abortion because non-physician clinicians are barred, local providers can be excluded, and telehealth provision and remote prescribing are eliminated.
Providers and health systems risk permanent exclusion from Medicare without normal appeal or reinstatement procedures, increasing the chance that clinicians will be removed from the program permanently and deterring providers from offering care to Medicare patients.
Including off‑label uses in the definition of 'abortion-inducing drug' creates legal uncertainty and could criminalize or penalize legitimate medical uses of these drugs, chilling standard clinical practice and deterring providers from prescribing for non‑abortion indications.
Based on analysis of 2 sections of legislative text.
Prohibits individuals or entities that participate in Medicare from prescribing, administering, dispensing, or furnishing an abortion‑inducing drug on or after enactment unless four conditions are met: the provider is a physician, performs a physical exam, is physically present in the same room when the patient is given or uses the drug, and schedules an in‑person follow‑up visit within 14 days. Violation triggers permanent exclusion from Medicare participation and certain review or reinstatement provisions are made inapplicable. The law also defines “abortion‑inducing drug” broadly (including off‑label uses) and defines “unborn child” by cross‑reference to federal law, creating a narrow path for medication abortion services through Medicare and restricting telehealth provision of such drugs for Medicare patients.
Introduced February 13, 2025 by W. Greg Steube · Last progress February 13, 2025